Australia - English - Department of Health (Therapeutic Goods Administration)

bristol-myers squibb australia pty ltd - abatacept, quantity: 125.875 mg - injection - excipient ingredients: dibasic sodium phosphate; nitrogen; water for injections; sucrose; poloxamer; monobasic sodium phosphate - orencia in combination with methotrexate is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have had an insufficient response or intolerance to other disease modifying anti-rheumatic drugs (dmards), such as methotrexate or tumour necrosis factor (tnf) blocking agents. a reduction in the progression of joint damage and improvement in physical function have been demonstrated during combination treatment with orencia and methotrexate.,orencia in combination with methotrexate is also indicated in the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate.,orencia is indicated for reducing signs and symptoms in paediatric patients 6 years of age and older with moderately to severely active polyarticular juvenile idiopathic arthritis who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (dmards). orencia may be used as monotherapy or concomitantly with methotrexate (mtx). (there is no clinical trial data for the use of orencia subcutaneous formulation in children, therefore its use in children cannot be recommended.),orencia is indicated for the treatment of active psoriatic arthritis (psa) in adults when the response to previous disease-modifying anti-rheumatic drug (dmard) therapy has been inadequate. orencia can be used with or without non-biologic dmards.,orencia should not be administered concurrently with other biological dmards (eg, tnf inhibitors, rituximab, or anakinra).

Australia - English - Department of Health (Therapeutic Goods Administration)

neo health (otc) pty ltd - naproxen sodium, quantity: 275 mg - capsule, soft - excipient ingredients: brilliant blue fcf; propylene glycol; purified water; partially dehydrated liquid sorbitol; lactic acid; povidone; glycerol; macrogol 600; gelatin; titanium dioxide; butan-1-ol; isopropyl alcohol; strong ammonia solution; simethicone; ethanol; shellac; sulfuric acid - for the relief of symptoms associated with periods, such as pain from menstrual cramps (i.e. symptomatic treatment of primary dysmenorrhoea).

Australia - English - Department of Health (Therapeutic Goods Administration)

neo health (otc) pty ltd - benzydamine hydrochloride, quantity: 3 mg/ml - spray, solution - excipient ingredients: glycerol; purified water; peg-35 castor oil; saccharin sodium; ethanol; flavour - for the temporary relief of painful conditions of the oral cavity including tonsillitis, sore throat, radiation mucositis, aphthous ulcers, post-orosurgical and periodontal procedures, pharyngitis, swelling, redness and inflammatory conditions.

Australia - English - Department of Health (Therapeutic Goods Administration)

neo health (otc) pty ltd - diclofenac potassium, quantity: 25 mg - tablet, film coated - excipient ingredients: sodium lauryl sulfate; macrogol 6000; hypromellose; magnesium stearate; crospovidone; mannitol; potassium bicarbonate; macrogol 400 - as short-term treatment (up to one week) for the relief of acute pain states in which there is an inflammatory component. treatment of acute migraine attacks (with or without aura). symptomatic treatment of primary dysmenorrhoea.

Australia - English - Department of Health (Therapeutic Goods Administration)

neo health (otc) pty ltd - senna leaf dry, quantity: 2.5 mg/ml (equivalent: hydroxyanthracene glycosides calculated as sennoside b, qty 1.5 mg/ml) - oral liquid, solution - excipient ingredients: xanthan gum; maltitol; methyl hydroxybenzoate; propyl hydroxybenzoate; potassium sorbate; simethicone; citric acid; flavour - decrease/reduce/relieve constipation

Australia - English - Department of Health (Therapeutic Goods Administration)

neo health (otc) pty ltd - benzydamine hydrochloride, quantity: 1.5 mg/ml - spray, solution - excipient ingredients: glycerol; methyl hydroxybenzoate; ethanol; polysorbate 20; quinoline yellow; sodium bicarbonate; patent blue v; saccharin; purified water; flavour - for the temporary relief of painful conditions of the oral cavity including tonsillitis, sore throat, radiation mucositis, aphthous ulcers, post-orosurgical and periodontal procedures, pharyngitis, swelling, redness and inflammatory conditions.

Australia - English - Department of Health (Therapeutic Goods Administration)

neo health (otc) pty ltd - glycyrrhiza glabra, quantity: 93 microlitre/ml (equivalent: glycyrrhiza glabra, qty 33.33 mg/ml); silybum marianum, quantity: 93 microlitre/ml (equivalent: silybum marianum, qty 33.33 mg/ml); mentha x piperita, quantity: 47 microlitre/ml (equivalent: mentha x piperita, qty 16.67 mg/ml); chelidonium majus, quantity: 93 microlitre/ml (equivalent: chelidonium majus, qty 33.33 mg/ml); carum carvi, quantity: 93 microlitre/ml (equivalent: carum carvi, qty 33.33 mg/ml); matricaria chamomilla, quantity: 186 microlitre/ml (equivalent: matricaria chamomilla, qty 66.67 mg/ml); angelica archangelica, quantity: 93 microlitre/ml (equivalent: angelica archangelica, qty 33.33 mg/ml); melissa officinalis, quantity: 93 microlitre/ml (equivalent: melissa officinalis, qty 33.33 mg/ml); iberis amara, quantity: 209 microlitre/ml (equivalent: iberis amara, qty 75 mg/ml) - oral liquid - excipient ingredients: - decrease/reduce/relieve flatulence/carminative ; relief of symptoms of medically diagnosed irritable bowel syndrome (linked indication:help reduce occurrence of symptoms of medically diagnosed irritable bowel syndrome); maintain/support healthy digestive system function ; maintain/support healthy digestion ; maintain/support digestive system health ; helps reduce occurrence of symptoms of indigestion/dyspepsia ; decrease/reduce/relieve symptoms of indigestion/dyspepsia ; relieve digestive discomfort

Australia - English - Department of Health (Therapeutic Goods Administration)

neo health (otc) pty ltd - paracetamol, quantity: 500 mg - tablet, uncoated - excipient ingredients: magnesium stearate; povidone; pregelatinised maize starch; sodium metabisulfite - temporary relief of pain associated with headache, migraine headache, tension headache, sinus pain, toothache, dental procedures, backache, muscular aches and pains, arthritis, osteoarthritis, rheumatic pain, period pain, fibrositis, neuralgia, sore throat, tennis elbow, and colds and flu. reduces fever.

Australia - English - Department of Health (Therapeutic Goods Administration)

neo health (otc) pty ltd - paracetamol, quantity: 500 mg - tablet, uncoated - excipient ingredients: pregelatinised maize starch; sodium metabisulfite; povidone; magnesium stearate - temporary relief of pain associated with headache, migraine headache, tension headache, sinus pain, toothache, dental procedures, backache, muscular aches and pains, arthritis, osteoarthritis, rheumatic pain, period pain, fibrositis, neuralgia, sore throat, tennis elbow, and colds and flu. reduces fever.

Australia - English - Department of Health (Therapeutic Goods Administration)

neo health (otc) pty ltd - amorolfine hydrochloride, quantity: 55.7 mg/ml - application - excipient ingredients: ethanol; ammonio methacrylate copolymer; ethyl acetate; butyl acetate; triacetin - for the treatment of onychomycoses caused by dermatophytes, yeasts and moulds.